P
Philippe L. Bedard
Researcher at Princess Margaret Cancer Centre
Publications - 363
Citations - 13661
Philippe L. Bedard is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 50, co-authored 305 publications receiving 9674 citations. Previous affiliations of Philippe L. Bedard include National Health Service & American Association For Cancer Research.
Papers
More filters
Journal ArticleDOI
Tumour heterogeneity in the clinic
Philippe L. Bedard,Aaron R. Hansen,Aaron R. Hansen,Mark J. Ratain,Lillian L. Siu,Lillian L. Siu +5 more
TL;DR: A large number of cancer cells with unique genomes in the same patient may exist across different geographical regions of a tumour or evolve over time, called intratumour heterogeneity, and Sequencing technologies can be used to characterize intratumours heterogeneity at diagnosis, monitor clonal dynamics during treatment and identify the emergence of clinical resistance during disease progression.
Journal ArticleDOI
AACR project genie: Powering precision medicine through an international consortium
Shawn M. Sweeney,Ethan Cerami,Alexander S. Baras,Trevor J. Pugh,Nikolaus Schultz,Thomas Stricker,James Lindsay,C. Del Vecchio Fitz,Priti Kumari,Christine M. Micheel,K. Shaw,Jianjiong Gao,Nicola Moore,Cyriac Kandoth,Brendan Reardon,Eva M Lepisto,Stuart Gardos,Kristen K. Dang,Justin Guinney,Larsson Omberg,Thomas Yu,Benjamin Gross,Zachary J. Heins,David M. Hyman,Barrett J. Rollins,Charles L. Sawyers,David B. Solit,Deborah Schrag,Victor E. Velculescu,Fabrice Andre,Philippe L. Bedard,Mia Levy,Gerrit A. Meijer +32 more
Journal ArticleDOI
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Rashmi Krishna Murthy,Sherene Loi,Alicia Okines,Elisavet Paplomata,Erika Hamilton,Sara A. Hurvitz,Nan Lin,Virginia F. Borges,Vandana G. Abramson,Carey K. Anders,Philippe L. Bedard,Mafalda Oliveira,Erik Jakobsen,Thomas Bachelot,Shlomit S. Shachar,Volkmar Müller,Sofia Braga,François Duhoux,Richard Greil,David Cameron,Lisa A. Carey,Giuseppe Curigliano,Karen A. Gelmon,Gabriel N. Hortobagyi,Ian E. Krop,Sibylle Loibl,Mark D. Pegram,Dennis J. Slamon,M Corinna Palanca-Wessels,Luke Walker,Wentao Feng,Eric P. Winer +31 more
TL;DR: In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free survival and overall survival outcomes than adding placebo.
Journal ArticleDOI
Sensitive tumour detection and classification using plasma cell-free DNA methylomes
Shu Yi Shen,Rajat Singhania,Gordon Fehringer,Ankur Chakravarthy,Michael H.A. Roehrl,Michael H.A. Roehrl,Michael H.A. Roehrl,Dianne Chadwick,Philip C. Zuzarte,Ayelet Borgida,Ting Ting Wang,Ting Ting Wang,Tiantian Li,Olena Kis,Zhen Zhao,Anna Spreafico,Tiago Medina,Yadon Wang,David Roulois,David Roulois,Ilias Ettayebi,Ilias Ettayebi,Zhuo Chen,Signy Chow,Tracy Murphy,Andrea Arruda,Grainne M. O'Kane,Jessica Liu,Mark Mansour,John Douglas Mcpherson,Catherine A. O’Brien,Natasha B. Leighl,Philippe L. Bedard,Neil E. Fleshner,Geoffrey Liu,Geoffrey Liu,Mark D. Minden,Steven Gallinger,Steven Gallinger,Anna Goldenberg,Trevor J. Pugh,Trevor J. Pugh,Michael M. Hoffman,Michael M. Hoffman,Scott V. Bratman,Scott V. Bratman,Rayjean J. Hung,Rayjean J. Hung,Daniel D. De Carvalho,Daniel D. De Carvalho +49 more
TL;DR: An immunoprecipitation-based protocol is developed to analyse DNA methylation in small quantities of circulating cell-free DNA, and can detect and classify cancers in plasma samples from several tumour types.
Journal ArticleDOI
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
Joaquin Mateo,Debyani Chakravarty,R. Dienstmann,S. Jezdic,Abel Gonzalez-Perez,Nuria Lopez-Bigas,Charlotte K.Y. Ng,Philippe L. Bedard,Giampaolo Tortora,J.-Y. Douillard,E.M. Van Allen,Nikolaus Schultz,Charles Swanton,Fabrice Andre,Lajos Pusztai +14 more
TL;DR: The first version of the ESMO Scale of Clinical Actionability for molecular Targets (ESCAT) defines clinical evidence-based criteria to prioritise genomic alterations as markers to select patients for targeted therapies.